FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SVB FINANCIAL GROUP
2. Date of Event Requiring Statement (MM/DD/YYYY)
12/22/2021 

3. Issuer Name and Ticker or Trading Symbol

ACHIEVE LIFE SCIENCES, INC. [ACHV]
(Last)        (First)        (Middle)

3003 TASMAN DRIVE
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

SANTA CLARA, CA 95054      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Convertible Debt (1) (2)(3)(4)(5) (2)(3)(4)(5)Common Stock 802997  (2)(3)(4)(5)I See Footnotes (6)(10)
Convertible Debt (1) (2)(3)(4)(5) (2)(3)(4)(5)Common Stock 401498  (2)(3)(4)(5)I See Footnotes (7)(9)(10)
Convertible Debt (1) (2)(3)(4)(5) (2)(3)(4)(5)Common Stock 401498  (2)(3)(4)(5)I See Footnotes (8)(9)(10)

Explanation of Responses:
(1) This statement is being filed by SVB Financial Group ("SVB Financial"), SVB Innovation Credit Fund VIII, L.P. ("Fund VIII"), SVB Innovation Credit Partners VIII, LLC ("Fund VIII GP" and, together with Fund VIII, the "Fund VIII Entities"), Innovation Credit Fund VIII-A, L.P. ("Fund VIII-A") and SVB Innovation Credit Partners VIII-A, LLC ("Fund VIII-A GP" and, together with Fund VIII-A, the "Fund VIII-A Entities"). SVB Financial, the Fund VIII Entities and the Fund VIII-A Entities are referred to herein, collectively, as the "Reporting Persons".
(2) On December 22, 2021 (the "Effective Date"), Achieve Life Sciences, Inc. (the "Issuer") entered into a 2021 Contingent Convertible Debt Agreement (the "Convertible Debt Agreement"), by and among the Issuer, Silicon Valley Bank ("SVB") and Fund VIII (together with their respective successors and assigns, collectively, the "Lenders"). Pursuant to the Convertible Debt Agreement, the Lenders advanced an aggregate amount of $15,000,000 to the Issuer (the "Convertible Debt" or "Associated Debt"). The Associated Debt is convertible, at the election of each person or entity entitled to exercise the right to elect a voluntary conversion with respect to an interest in the Associated Debt (each, a "Conversion Right Holder" and collectively, the "Conversion Right Holders"),
(3) (Continued from Footnote 2), into a number of Common Stock shares equal to (A) the amount of Associated Debt (including interest accrued with respect to the Associated Debt that is required to be paid in kind by being added to the principal balance thereof) such Conversion Right Holder elects to convert, divided by (B) $9.34 (the "Conversion Right"). As of the Effective Date, SVB has (i) sold a participation interest in $3,750,000 of its interest in the Associated Debt (such portion of the Associated Debt, the "Participated Debt" and the remaining portion of the Associated Debt held by SVB, the "Remaining SVB Associated Debt"), and assigned the Conversion Right related to the Participated Debt to Fund VIII-A and (ii) assigned its Conversion Right with respect to the Remaining SVB Associated Debt to SVB Financial. The Conversion Right Holders may voluntarily convert all or any part of the Associated Debt at any time,
(4) (Continued from Footnote 3), provided that if the closing price per share of Issuer's Common Stock is equal to or greater than $24.00 for thirty (30) consecutive trading days, then the Associated Debt will mandatorily convert to Common Stock on the following trading day, and provided further, the conversion of Associated Debt into Common Stock is limited to an amount of Common Stock which would not result in (i) the maximum aggregate number of Common Stock issuable to all Conversion Right Holders exceeding 1,889,763 shares of Common Stock, as such number may be adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like occurring after the Effective Date or (ii) the maximum aggregate number of Common Stock of the Issuer owned or held by SVB Financial beneficially and/or of record exceeding 19.99% of the Issuer's then-total issued and outstanding shares of Common Stock.
(5) (Continued from Footnote 4), The Associated Debt will be convertible for so long as such indebtedness remains outstanding.
(6) Reflects Associated Debt (other than Participated Debt) held directly by SVB, with the related Conversion Right exercisable by SVB Financial.
(7) Reflects Associated Debt and the related Conversion Right held directly by Fund VIII. Fund VIII GP is the general partner of Fund VIII and may be deemed to beneficially own indirectly Associated Debt and the related Conversion Right held directly by Fund VIII.
(8) Reflects Participated Debt in which Fund VIII-A holds directly a participation interest and the related Conversion Right held directly by Fund VIII-A. Fund VIII-A GP is the general partner of Fund VIII-A and may be deemed to beneficially own indirectly an interest in Participated Debt and the related Conversion Right held directly by Fund VIII-A.
(9) SVB Financial may be deemed to beneficially own indirectly any Associated Debt (including interests in Participated Debt) and Conversion Rights held by the Fund VIII Entities and the Fund VIII-A Entities. SVB Financial is the manager of Fund VIII GP and Fund VIII-A GP and the investment adviser to Fund VIII and Fund VIII-A. Silicon Valley Bank is a wholly-owned subsidiary of SVB Financial.
(10) Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
SVB FINANCIAL GROUP
3003 TASMAN DRIVE
SANTA CLARA, CA 95054

X

SVB Innovation Credit Partners VIII, LLC
2770 SAND HILL ROAD
MENLO PARK, CA 94025

X

SVB Innovation Credit Fund VIII, L.P.
2770 SAND HILL ROAD
MENLO PARK, CA 94025

X

SVB Innovation Credit Partners VIII-A, LLC
2770 SAND HILL ROAD
MENLO PARK, CA 94025

X

Innovation Credit Fund VIII-A, L.P.
2770 SAND HILL ROAD
MENLO PARK, CA 94025

X


Signatures
/s/ Karen Hon, Chief Accounting Officer, SVB Financial Group12/29/2021
**Signature of Reporting PersonDate

/s/ Andrew Olson, Chief Financial Officer of SVB Innovation Credit Partners VIII, LLC12/29/2021
**Signature of Reporting PersonDate

/s/ Andrew Olson, Chief Financial Officer of SVB Innovation Credit Partners VIII, LLC, general partner of SVB Innovation Credit Fund VIII, L.P.12/29/2021
**Signature of Reporting PersonDate

/s/ Andrew Olson, Chief Financial Officer of SVB Innovation Credit Partners VIII-A, LLC12/29/2021
**Signature of Reporting PersonDate

/s/ Andrew Olson, Chief Financial Officer of SVB Innovation Credit Partners VIII-A, LLC, general partner of Innovation Credit Fund VIII-A, L.P.12/29/2021
**Signature of Reporting PersonDate

Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Achieve Life Sciences Charts.
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Achieve Life Sciences Charts.